Navigation Links
Study shows benefit of new maintenance therapy for multiple myeloma
Date:5/11/2012

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.

Unfortunately, multiple myeloma continues to progress even after a transplant. A study published today in the New England Journal of Medicine offers promising news about a new long-term therapy, lenalidomide, that can be used after transplantation to slow down the progression of the disease.

Thomas Shea, MD, Director of the Bone Marrow and Stem Cell Transplant Program and Associate Director for Outreach Programs at UNC Lineberger and Don Gabriel, MD, Professor of Medicine in the division of hematology/oncology, were both co-authors on the clinical trial, which measured the effect of maintenance lenalidomide therapy on disease-free progression after transplant.

The phase 3 study demonstrated that maintenance therapy with lenalidomide, an oral drug that can be taken for many months or even years, is associated with significant improvement in outcomes for patients with newly diagnosed myeloma who have undergone a transplant. The probability of surviving free of disease progression (the primary end point) for three years was 59 percent in the lenalidomide group, as compared with 35 percent in the placebo group.

"The results of this trial will change our treatment of multiple myeloma patients," said Dr. Shea.

"While lenalidomide has some risks, including an increase in people developing second cancers, it generally appears to be well-tolerated when given long-term and was associated with a delay in time to progression of the myeloma as well as an improvement in overall survival" he added.

Shea noted that another study in France showed similar improvement in delaying progression of the myeloma following transplant, but did not improve how long patients lived after their transplant compared to those receiving a placebo. Additional studies need to be conducted and longer follow-up of the current studies will need to be undertaken to confirm whether there is a real survival benefit of lenalidomide therapy for these patients.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. First, Second Kidney Transplants Have Similar Success: Study
2. Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says
3. Email Vacations Boost Job Productivity, Lower Stress: Study
4. Stem Cell Study Shows Promising Results Against Heart Failure
5. Fitness in Middle Age Lowers Medical Costs Later: Study
6. Smell Tests Dont Predict Alzheimers, Study Finds
7. Only Half of Meds Taken by Kids Have Adequate Safety Info: Study
8. OHSU study: Misdiagnosis of MS is costing health system millions per year
9. Evolution May Explain Runners High, Study Says
10. Infection Causes 1 in 6 Cancers Worldwide: Study
11. Wheelchair Breakdowns on the Rise, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2016)... (PRWEB) , ... May 01, 2016 , ... ... http://www.womensexcellence.com that gives new mothers a better understanding of what to ... to call, · Adjusting to baby postpartum, · The blues and depression, · ...
(Date:4/30/2016)... ... April 30, 2016 , ... Create an abstract ... can distort and manipulate three-dimensional shapes with ease all within Apple Motion ... lines, polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, twist, ...
(Date:4/30/2016)... (PRWEB) , ... April 30, ... ... by CBC News on April 4th, 2016 questioned the use of the ... to EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... In an ... mother and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent ... famous youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members ... celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural Health Care ... Cumming), offers a 70% tax credit to individuals and corporations which donate directly to ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... JACKSONVILLE, Florida , April 28, 2016 ... in the development of innovative peptide and gene-based immunotherapeutics and ... announced it will be presenting at the 3rd Annual ... - 5 th , 2016 at Caesars Palace in Las ... at 8.00 am on Wednesday, May 4 th by ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
(Date:4/27/2016)... Elekta today announced that its ... the focal point of seven scientific presentations at ESTRO ... Radiotherapy & Oncology, taking place April 29 - May ... system and a high-field MRI scanner with sophisticated software ... anatomy in real time. The MR-linac is designed to ...
Breaking Medicine Technology: